Halozyme Therapeutics (HALO) Finished Goods (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Finished Goods data on file, last reported at $113.4 million in Q1 2026.

• Finished Goods for Q1 2026 came in at $113.4 million, down 20.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $113.4 million (down 20.85% YoY), and the FY2025 annual result was $144.5 million, up 1.06% from the prior year.
• Finished Goods slipped to $113.4 million in Q1 2026 per HALO's latest filing, from $144.5 million in the prior quarter.
• Over five years, Finished Goods peaked at $164.9 million in Q2 2025 and troughed at $31.2 million in Q1 2022.
• A 5-year average of $96.6 million and a median of $95.8 million in 2024 frame the typical range for Finished Goods.
• The sharpest annual moves came in 2024 and 2026: Finished Goods soared 122.79% in 2024, then declined 20.85% in 2026.
• A 5-year view of Finished Goods shows it stood at $46.0 million in 2022, then surged by 52.12% to $69.9 million in 2023, then surged by 104.41% to $142.9 million in 2024, then advanced by 1.06% to $144.5 million in 2025, then dropped by 21.52% to $113.4 million in 2026.
• Business Quant data shows HALO's Finished Goods at $113.4 million in Q1 2026, $144.5 million in Q4 2025, and $161.6 million in Q3 2025.